TB006
TB006 is a humanized monoclonal antibody targeting galectin-3, which is suspected to be a factor in the formation of amyloid plaques.[1][2][3]
References
[edit]- ^ Cummings, Jeffrey L.; Osse, Amanda M. Leisgang; Kinney, Jefferson W. (October 2023). "Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification". Drugs. 83 (15): 1387–1408. doi:10.1007/s40265-023-01938-w. PMC 10582128.
- ^ Rasool, Suhail; Patel, Pooja; Johansson, Jenny; Voloboueva, Ludmila; Lee, Sangmi; Sun, Jessica; Lan, Xi; Ahmed, Taufeeq; Sun, Dongxu (December 2022). "Potential Reversal of Alzheimer's Disease pathology by Antibody TB006 Targeting Galectin‐3, the Root Cause of Oligomerization of Amyloid Proteins". Alzheimer's & Dementia. 18 (S10). doi:10.1002/alz.060393.
- ^ Chaurasiya, Akash; Katke, Sumeet; Panchal, Kanan; Nirmal, Jayabalan (2023). "Biologics for the management of dementia". Nanomedicine-Based Approaches for the Treatment of Dementia: 193–234. doi:10.1016/B978-0-12-824331-2.00001-7.